Humana (HUM) Q2 Revenue Rises 10%
Werte in diesem Artikel
Humana (NYSE:HUM), one of the largest U.S. health insurers with a major focus on Medicare Advantage and integrated healthcare services, reported its second quarter 2025 results on July 30, 2025. The most notable headline was an adjusted earnings per share (EPS) of $6.27, and revenue of $32.4 billion, both topping Wall Street estimates of $5.92 (Non-GAAP EPS) and $31.9 billion (GAAP revenue), respectively. Despite exceeding expectations, adjusted EPS fell from $6.96 in the prior year period, while GAAP revenue rose from $29.54 billion in Q2 2024, showing robust top-line growth year over year but ongoing earnings pressure. The company raised its adjusted EPS guidance and revenue targets, reflecting management’s confidence in the company’s core strategy even as challenges remain in margin performance and Medicare Advantage membership trends. Source: Analyst estimates for the quarter provided by FactSet. Humana is a major health insurer known for its concentration in Medicare Advantage—a type of health insurance plan for seniors and certain disabled individuals, provided through contracts with the U.S. government. In recent years, it has prioritized government contracts, with a particular emphasis on Medicare Advantage, Medicaid, and related services, which accounted for 85% of premiums and services revenue in FY2024.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Übrigens: Humana und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Humana
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Humana
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: MotleyFool
Nachrichten zu Humana Inc.
Analysen zu Humana Inc.
Datum | Rating | Analyst | |
---|---|---|---|
12.08.2019 | Humana Overweight | Cantor Fitzgerald | |
13.09.2018 | Humana Overweight | Barclays Capital | |
09.11.2017 | Humana Sector Perform | RBC Capital Markets | |
20.10.2017 | Humana Outperform | BMO Capital Markets | |
05.04.2017 | Humana Hold | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
12.08.2019 | Humana Overweight | Cantor Fitzgerald | |
13.09.2018 | Humana Overweight | Barclays Capital | |
20.10.2017 | Humana Outperform | BMO Capital Markets | |
24.01.2017 | Humana Hold | Stifel, Nicolaus & Co., Inc. | |
05.05.2016 | Humana Buy | Stifel, Nicolaus & Co., Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
09.11.2017 | Humana Sector Perform | RBC Capital Markets | |
05.04.2017 | Humana Hold | Deutsche Bank AG | |
07.12.2016 | Humana Hold | Cantor Fitzgerald | |
13.10.2016 | Humana Sector Perform | RBC Capital Markets | |
22.07.2016 | Humana Mkt Perform | FBR Capital |
Datum | Rating | Analyst | |
---|---|---|---|
14.03.2008 | Humana neues Kursziel | Lehman Brothers Inc. | |
03.02.2006 | Update Humana Inc.: Underperform | Credit Suisse First Boston | |
26.01.2006 | Update Humana Inc.: Reduce | UBS |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Humana Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen